Localized Morbilliform Drug Eruption Following Sildenafil Exposure: A Case Report.
4 affiliations
- 1Department of Medicine, Ethio Tebib Hospital, Addis Ababa, ETH.
- 2Department of Medicine, Bethel Medical College, Addis Ababa, ETH.
- 3Department of Surgery, Teklehaimanot General Hospital, Addis Ababa, ETH.
- 4Department of Surgery, Debre Berhan University, Debre Berhan, ETH.
Abstract
Sildenafil is a commonly used medication for the treatment of erectile dysfunction and is generally well-tolerated. Cutaneous adverse drug reactions associated with sildenafil are uncommon and have been described in various clinical forms. We report a case of a 34-year-old man with no significant medical history who developed an asymptomatic, localized morbilliform eruption four days after taking a single 100 mg dose of sildenafil, representing his first reported exposure. The eruption consisted of erythematous macules and papules confined to the back, without mucosal involvement, facial edema, vesiculation, bullae formation, purpura, desquamation, or systemic symptoms. Complete blood count and serum biochemical investigations were unremarkable, with no eosinophilia or evidence of hepatic, renal, or hematologic abnormalities. No other medications, supplements, recent infectious illness, or other apparent triggers were identified. Based on the clinical presentation and temporal relationship, a sildenafil-associated morbilliform drug eruption was considered. The Naranjo Adverse Drug Reaction Probability Scale yielded a score of 6, indicating a probable adverse drug reaction. The patient was treated conservatively with antihistamines, and the eruption resolved spontaneously without corticosteroid therapy or other specific interventions. This case highlights an uncommon localized morbilliform eruption following sildenafil exposure and emphasizes the importance of recognizing this potential adverse reaction.
Related
- Systemic cytokine signatures associated with volcanic emisions exposure and respiratory disease after the cumbre vieja eruption-ashes project
- Case Report: Clinical improvement of localized chronic eczema following multisegmental paraspinal electroacupuncture
- Understanding patient perspectives and preferences on sildenafil orodispersible formulation: a survey-based evaluation of men using erectile dysfunction medications.
- Neonatal Hypotonia Following in Utero Exposure to Antidepressant Drugs
- Respiratory health outcomes following co-exposure to subchronic high temperature, episodic wildfire smoke exposure, and high-cholesterol diet
BibTeX
@article{habte2026localized,
title = {{Localized Morbilliform Drug Eruption Following Sildenafil Exposure: A Case Report.}},
author = {Yoseph M Habte and Makida M Habte and Esimael M Abdu and Binyam M Habte},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.117354},
url = {https://europepmc.org/article/MED/42968972},
note = {CC BY},
}
RIS
TY - JOUR
TI - Localized Morbilliform Drug Eruption Following Sildenafil Exposure: A Case Report.
AU - Yoseph M Habte
AU - Makida M Habte
AU - Esimael M Abdu
AU - Binyam M Habte
PY - 2026
DA - 2026/10/02
JO - Cureus
DO - 10.7759/cureus.117354
UR - https://europepmc.org/article/MED/42968972
AB - Sildenafil is a commonly used medication for the treatment of erectile dysfunction and is generally well-tolerated. Cutaneous adverse drug reactions associated with sildenafil are uncommon and have been described in various clinical forms. We report a case of a 34-year-old man with no significant medical history who developed an asymptomatic, localized morbilliform eruption four days after taking a single 100 mg dose of sildenafil, representing his first reported exposure. The eruption consisted of erythematous macules and papules confined to the back, without mucosal involvement, facial edema, vesiculation, bullae formation, purpura, desquamation, or systemic symptoms. Complete blood count and serum biochemical investigations were unremarkable, with no eosinophilia or evidence of hepatic, renal, or hematologic abnormalities. No other medications, supplements, recent infectious illness, or other apparent triggers were identified. Based on the clinical presentation and temporal relationship, a sildenafil-associated morbilliform drug eruption was considered. The Naranjo Adverse Drug Reaction Probability Scale yielded a score of 6, indicating a probable adverse drug reaction. The patient was treated conservatively with antihistamines, and the eruption resolved spontaneously without corticosteroid therapy or other specific interventions. This case highlights an uncommon localized morbilliform eruption following sildenafil exposure and emphasizes the importance of recognizing this potential adverse reaction.
SN - 2168-8184
ER -